Literature DB >> 32784237

Guttate psoriasis secondary to COVID-19.

Kohilan Gananandan1, Benjamin Sacks2, Iain Ewing3.   

Abstract

Entities:  

Keywords:  dermatology; infectious diseases

Mesh:

Substances:

Year:  2020        PMID: 32784237      PMCID: PMC7418771          DOI: 10.1136/bcr-2020-237367

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.

Description

A 38-year-old man presented with symptoms of fever and dry cough. There was a past medical history of chronic plaque psoriasis with a single active psoriatic plaque affecting the lateral aspect of the right ankle. The patient was using no regular medication and no topical therapy for psoriasis at the time of presentation with respiratory symptoms. There were no throat symptoms and pharyngeal examination was normal. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) RNA was detected from a nasopharyngeal swab confirming COVID-19 infection. At day 6 following the onset of fever, multiple erythematous lesions began to form inferior to the knee on the anterior and lateral aspect of the right lower limb. At day 22 the patient sought a dermatological opinion as these lesions had failed to improve. On examination there were multiple drop-like well circumscribed salmon pink erythematous papules with a fine scale, measuring between 4 and 12 mm in size, consistent with guttate psoriasis (figure 1). Blood tests showed IgG positivity for SARS-CoV2, with otherwise normal full blood count, C-reactive protein and routine biochemistry. Antistreptolysin O titre was negative at <200 IU/mL.
Figure 1

Right lower limb 22 days after the onset of symptoms of COVID-19. Multiple drop-like well circumscribed salmon pink erythematous papules with a fine scale, measuring between 4 and 12 mm in size, consistent with guttate psoriasis. A chronic psoriatic plaque is present on the lateral aspect of the right ankle.

Right lower limb 22 days after the onset of symptoms of COVID-19. Multiple drop-like well circumscribed salmon pink erythematous papules with a fine scale, measuring between 4 and 12 mm in size, consistent with guttate psoriasis. A chronic psoriatic plaque is present on the lateral aspect of the right ankle. Treatment was commenced with topical readily diluted betamethasone 0.025% cream applied two times per day. There was significant clinical improvement on review after 2 weeks, with no new lesions and regression of those previously identified (figure 2).
Figure 2

Right lower limb after 2 weeks of topical treatment. Significant clinical improvement on review after 2 weeks, with no new lesions and regression of those previously identified.

Right lower limb after 2 weeks of topical treatment. Significant clinical improvement on review after 2 weeks, with no new lesions and regression of those previously identified. Guttate psoriasis is known to occur after acute infection. It is associated with genetic and environmental factors, and usually arises in children or younger adults.1 It is classically associated with streptococcal infection,2 although respiratory virus infection can also trigger psoriatic flares in the absence of concurrent streptococcal infection.3 A possible mechanism for viral infection leading to psoriatic flare is dysregulation of innate immune response following stimulation of toll-like receptor 3 by viral RNA leading to production of pathogenic cytokines/chemokines IL-36-γ and CXCL8.3 This is the first case reported of an acute guttate flare of chronic psoriasis secondary to confirmed COVID-19 infection. Guttate psoriasis is known to have a better prognosis than other types of psoriasis and rapid involution with long-term remission is common.4 The quality of evidence for treatment of guttate psoriasis is very low with an absence of trials assessing the efficacy and safety of phototherapy, topical or systemic drugs.1 We observed rapid induction of remission with readily diluted betamethasone 0.025% cream. I initially experienced only mild symptoms of COVID-19 and was recovering in self-isolation. Almost a week into the illness I began to develop a new rash on my right leg that spread quite rapidly over the next few days. I have a previous history of psoriasis, which had been stable for many years so despite being a practicing physician, I did not immediately link the new rash with this problem. Things continued to get worse over the next 2 weeks so I sought an urgent dermatology consultation. The rash was recognised as a flare of guttate psoriasis and I was relieved that it responded so quickly to betamethasone cream. Now, around a month down the line, things are much better and my skin has almost healed. When I looked up COVID-19 as a cause for guttate psoriasis, I realised this had not been previously reported, so I was keen to collaborate as a co-author to report this new association. Guttate psoriasis manifests as multiple drop-like well circumscribed erythematous papules and is commonly associated with acute, particularly streptococcal, infection. Severe acute respiratory syndrome coronavirus 2 was identified as the infective precipitant in this case and further such cases may emerge as we learn more about the clinical manifestations of the COVID-19 illness. High-quality evidence for treatment of guttate psoriasis is lacking, but the prognosis is good and rapid involution is common.
  4 in total

1.  The role of streptococcal infection in the initiation of guttate psoriasis.

Authors:  N R Telfer; R J Chalmers; K Whale; G Colman
Journal:  Arch Dermatol       Date:  1992-01

2.  Clinical course of guttate psoriasis: long-term follow-up study.

Authors:  Hyun-Chang Ko; Seung-Wook Jwa; Margaret Song; Moon-Bum Kim; Kyung-Sool Kwon
Journal:  J Dermatol       Date:  2010-10       Impact factor: 4.005

3.  Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.

Authors:  Annabel Maruani; Mahtab Samimi; Natasha Stembridge; Rania Abdel Hay; Elsa Tavernier; Carolyn Hughes; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2019-04-08

4.  Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds.

Authors:  E Sbidian; M Madrange; M Viguier; M Salmona; S Duchatelet; A Hovnanian; A Smahi; J Le Goff; H Bachelez
Journal:  Br J Dermatol       Date:  2019-08-20       Impact factor: 9.302

  4 in total
  20 in total

Review 1.  Roles of Infection in Psoriasis.

Authors:  Shihui Zhou; Zhirong Yao
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

Review 2.  Relevance Between COVID-19 and Host Genetics of Immune Response.

Authors:  Ibrahim Taher; Abdulrahman Almaeen; Amany Ghazy; Mohamed Abu-Farha; Arshad Mohamed Channanath; Sumi Elsa John; Prashantha Hebbar; Hossein Arefanian; Jehad Abubaker; Fahd Al-Mulla; Thangavel Alphonse Thanaraj
Journal:  Saudi J Biol Sci       Date:  2021-07-17       Impact factor: 4.219

3.  The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.

Authors:  Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi
Journal:  J Autoimmun       Date:  2020-12-14       Impact factor: 7.094

4.  Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.

Authors:  Kuo-Tung Tang; Bo-Chueh Hsu; Der-Yuan Chen
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

5.  National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.

Authors:  Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steven R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin
Journal:  J Am Acad Dermatol       Date:  2021-01-07       Impact factor: 15.487

6.  SARS-CoV-2 and guttate psoriasis: A case report and review of literature.

Authors:  Elrazi Ali; Abdelaziz Mohamed; Joud Abuodeh; Mhd Kutaiba Albuni; Najlaa Al-Mannai; Sarah Salameh; Mahir Petkar; Elmukhtar Habas
Journal:  Clin Case Rep       Date:  2021-07-16

7.  New-onset guttate psoriasis secondary to COVID-19.

Authors:  Meriem Rouai; Faten Rabhi; Nada Mansouri; Kahena Jaber; Raouf Dhaoui
Journal:  Clin Case Rep       Date:  2021-07-28

Review 8.  Biologics for Psoriasis during the COVID-19 Pandemic.

Authors:  Koji Kamiya; Mayumi Komine; Mamitaro Ohtsuki
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

Review 9.  Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.

Authors:  Elia Rosi; Maria Thais Fastame; Antonella Di Cesare; Gianmarco Silvi; Nicola Pimpinelli; Francesca Prignano
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

10.  National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1.

Authors:  Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steve R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; Jessica Smith; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin
Journal:  J Am Acad Dermatol       Date:  2020-09-04       Impact factor: 15.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.